<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273559</url>
  </required_header>
  <id_info>
    <org_study_id>TL092005-1</org_study_id>
    <nct_id>NCT00273559</nct_id>
  </id_info>
  <brief_title>A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids</brief_title>
  <official_title>A Single Center, Open Label, Comparative, Controlled Trial to Assess the Risks and Benefits of Steroid Elimination vs. Steroid Therapy After Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Hospital Transplant Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida Hospital Transplant Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the risks and benefits of steroid elimination versus&#xD;
      steroid therapy in renal transplant patients particularly looking at the effects on bone&#xD;
      mass, lipids, hypertension, and new onset diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of steroids after renal transplantation has been invaluable, resulting in higher&#xD;
      rates of long term survival of the transplanted kidney. However, post-operative steroids are&#xD;
      also associated with frequent post-operative and long term complications. There have been&#xD;
      steroid elimination studies analyzing acute rejection rates, graft and patient survival.&#xD;
      These studies show that many patients can safely have steroids withdrawn with equivalent&#xD;
      results whan compared to those who remain on steroids.&#xD;
&#xD;
      With this study we will be using a rapid steroid elimination protocol for 40 patients and&#xD;
      compare 20 patients who remain on steroids. We hope to show a decreased rate of complications&#xD;
      such as osteopenia/osteoporosis, new onset diabetes, and a decrease in cardiovascular risk&#xD;
      factors such as hyperlipidemia and hypertension.&#xD;
&#xD;
      Solumedrol will be given to all patients at the time of transplant followed by a prednisone&#xD;
      taper. Those remaining on steroids will be discharged on prednisone 5 mg daily. Those in whom&#xD;
      steroids are eliminated will be off prednisone by discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (health survey)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-transplant diabetes</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of osteopenia/osteoporosis at baseline and one year</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>subjects who remain on steroids after discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Subjects will be off steroids at the time of discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        de novo renal transplant recipients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing a single renal transplant from deceased or living donor&#xD;
&#xD;
          -  Adults 18 years and older&#xD;
&#xD;
          -  First or second renal transplant&#xD;
&#xD;
          -  Capable of understanding the purposes of the study, has given written informed&#xD;
             consent, and agrees to comply with the study requirements&#xD;
&#xD;
          -  Women of child bearing age should have a negative serum pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Greater than 2 renal transplants&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Patients receiving immunosuppressive therapy within the preceding 28 days for first&#xD;
             transplant and 3 months for the second transplant&#xD;
&#xD;
          -  Cold ischemia time &gt; 30 hours&#xD;
&#xD;
          -  History of malignancy in the last 5 years except successfully treated localized&#xD;
             non-melanoma skin cancer&#xD;
&#xD;
          -  HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) positive serology&#xD;
&#xD;
          -  Loss of previous transplant in &lt; 1 year&#xD;
&#xD;
          -  History of non-compliance&#xD;
&#xD;
          -  Any form of substance abuse, psychiatric disorder or condition which, in the opinion&#xD;
             of the investigator, may impair communication with the investigator or compliance with&#xD;
             study procedures&#xD;
&#xD;
          -  Multiple organ transplant&#xD;
&#xD;
          -  History of chronic steroid use except for inhaled steroids for asthma&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Women of childbearing potential not willing to use a reliable form of contraception.&#xD;
&#xD;
          -  Patients with severe medical condition(s) that, in the view of the investigator,&#xD;
             prohibits participation in the study&#xD;
&#xD;
          -  Known sensitivity to study drugs or class of study drugs&#xD;
&#xD;
          -  Use of any investigational agent in the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Angelis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Transplant Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Hospital Transplant Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>January 5, 2006</study_first_submitted>
  <study_first_submitted_qc>January 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <last_update_submitted>May 8, 2008</last_update_submitted>
  <last_update_submitted_qc>May 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Michael Angelis, MD</name_title>
    <organization>Florida Hospital Transplant Center</organization>
  </responsible_party>
  <keyword>Renal Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

